Investors have long seen the vast healthcare industry as a defensive sector. In good times and bad, consumers will still need everything from pharmaceuticals to medical devices to for-profit hospitals. But how strong is the healthcare industry today? Companies in all healthcare segments are wrestling with ongoing pressure to reduce costs from governments and private insurers alike. With a wave of maturities slowly approaching, how strong is the threat of US healthcare company defaults? At  10:34 we cross the Atlantic to take a closer look at risks and opportunities this year for healthcare companies based in Europe.Guests: Ola Hannoun-Costa, Corporate Finance Group, Associate Managing Director;  Jean-Yves Coupin, Vice President – Senior Analyst; Marie Fischer-Sabatie, Senior Vice President; and Frederic Duranson, Vice President – Senior Analyst, all of the Corporate Finance Group at Moody’s Investors Service.Host: Tania Hall, Vice President – Senior Research Writer, Moody’s Investors Service.To on this topic, visit the Behind the Bonds page on Moodys.com. (Some content available only to registered users or subscribers.)Related Research:Developments to watch in 2023: Humira biosimilar entry, obesity drugs and M&ACredit stress is rising, setting the stage for more downgrades and defaultsDevelopments to watch in 2023: US drug pricing policy, cost inflation and M&ARapid decline in COVID-19 testing, prices is credit negative for European laboratories

Ver todos los episodios